GLOBAL CANNABIS APPLICATIONS CORP
Better Patient Outcomes = Medical Cannabis Growth

GCAC

July 2019

April 2021

FORWARD LOOKING STATEMENTS

This Presentation (together with any supplements and any other information that may be furnished to prospective investors by **Global Cannabis Applications Corp**. ("**Global Cannabis**" or "**Global Cannabis Applications**") contains "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws (collectively "Forward-looking Information").

While Global Cannabis Applications considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause Global Cannabis Applications actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others, regulatory risks, the lack of a public market for the securities of Global Cannabis Applications, the limited operating history and financial track record of Global Cannabis Applications and the uncertainty as to revenues, reliance on key personnel, product liability, unfavorable publicity, management of growth and the difficulty in forecasting. Additionally, letter of intent for acquisitions that Global Cannabis has entered into may not be consummated or consummated on the terms disclosed by Global Cannabis. In the event that the letters of intent are not completed, or definitive agreements are not entered into Global Cannabis may not achieve the results that it is forecasting or the operating results that management believes are attainable in the event that the letters of intent are consummated.

Forward-looking Information is generally identifiably the use of the words:

"believes", "may", "plans", "will", "can" "anticipates", "intends", "budgets", "could", "estimates", "expects", "forecasts", "projects"
and similar expressions, and the negatives of such expressions.

Forward-looking Information in this Presentation includes, but is not limited to, statements concerning economic trends, the size of the market, the timing and scope of Global Cannabis Applications capital expenditures, the anticipated use of proceeds, financial forecasts, and the proposed ownership allocation.

Global Cannabis Applications has based this Forward-looking Information on factors and assumptions about future events and financial trends that it believe may affect its financial condition, results of operations, business strategy and financial needs, including the ability of Global Cannabis Applications to generate cash flow from operations and obtain necessary financing on acceptable terms, general economic, financial market, regulatory and political conditions in which Global Cannabis Applications operates, consumer interest in Global Cannabis Applications products, competitions, anticipated costs, government regulation of Global Cannabis Applications activities and products and in areas of taxation and environmental protection, the timely receipt of any required regulatory approvals, and Global Cannabis Applications ability to obtain qualified staff, equipment and services in a timely and cost efficient manner.

GCAC

MARKET VALUE : CANNABIS DATA

- The Global Medical Marijuana Market is estimated to reach USD 148.35 Billion by 2026*

- Marijuana is used for treating chronic pain that affects millions of people each year across the globe, thus increasing the demand for the product as a treatment procedure for medical conditions


The EU market is expected to be 40% of the global cannabis market by 2028

- EU
- North America
- South America
- Asia
- Middle East
- Australia
- Africa

Top 10 Pharma Companies by Market Cap

Johnson & Johnson $374B
Pfizer $241B
gsk $100B
MERCK $216B
AstraZeneca $103B
NOVARTIS $208B
abbvie $105B
SANOFI $107B
Lilly $108B
novo nordisk $123B

Market Cap Total $1.7T

This total is more than the nominal GDP of South Korea.

Big Pharma's Foray into Cannabis

Further legalization of medical cannabis will challenge Big Pharma's bottom line.

Medical cannabis could poach more than $4B from pharma sales annually.

Projected medical cannabis sales for 2019 alone will reach $5.9B, from an estimated 24 million patients.

If medical marijuana were to be made legal nationally, taxpayers could save $1.1 billion on Medicaid prescriptions each year.

Prescription Medication Spending by Condition

Pharma recognizes the EU as the fast growing and lucrative but one of the most heavily regulated medical cannabis markets in the world.

*Reports and Data

GCAC

OPPORTUNITY: DEMAND FOR CANNABIS DATA IS OUTPACING SUPPLY

- 564* – # of clinical medical cannabis trials globally

- 17 – # of clinical trials investigating efficacy of cannabis

- 20,000 - # of patients being supplied medical cannabis cannabis program

- 5 - # of years of Ireland's legislation approved cannabis trial program

- 2 - # of years France's Assemblée Nationale authorized

- 23.2% - CAGR growth of global analytics as a service

- USD 5.6 billion – estimated size of eClinical solutions 2019 market forecast period

GCAC Signs Data Sales Contract for Medical Cannabis Data

January 20, 2021 /

Vancouver, British Columbia, Canada, January 20, 2021 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis chain-of-custody compliance and data platform, today announced it has signed a definitive Data Sales Service Agreement ("Agreement") with Alqami. The partnership will enable GCAC to leverage Alqami's global buyer network and license the [...]

PRESS RELEASE

Map of ongoing clinical trials involving medicinal cannabis in Europe

● **COUNTRIES WITH ACTIVE CLINICAL TRIALS**

Austria, Bulgaria, Denmark, Germany, Hungary, Netherlands, Poland, Spain, Switzerland, United Kingdom

● **COUNTRIES WITH PILOT ACCESS SCHEMES**

Ireland, UK, France, Luxembourg, Denmark

CONDITIONS BEING INVESTIGATED

Arthritis, Cancer, Dermatomyositis, Diffuse Cutaneous Systemic Sclerosis, Endometriosis, Infantile Spasms, MS, Pain, Parkinsons, Rett Syndrome, Schizophrenia, Tourettes

Source: Prohibition Partners/Clinicaltrials.gov.
Note: Several trials are being carried out in multiple regions but are considered part of the same clinical trial.

GCAC

CHALLENGE: THE NET RESULT OF LACK OF DATA

NEWS

BNN Bloomberg

MARIJUANA | ARTICLE ▼

MARIJUANA Mar 8, 2021

Health Canada probing cannabis labelling amid Canopy Growth potency complaint

By **David George-Cosh**

Canada investigati...

David George-Cosh
Reporter
Follow | Archive

Health Canada is investigating complaints alleging inaccurately-labelled potency levels for some products sold by licensed pot producers, including industry leader Canopy Growth Corp.

One of the world's largest cannabis companies, is being investigated after claims that its certificates of analysis (THC/CBD test results) did not match the its TWD labels. The complaint from Pure Sunfarms states that 'Canopy is employing a static labelling approach'.

GCAC's Efixii was developed to ensure correct data reporting from cultivator to consumer.
This didn't have to happen…

GCAC

GCAC MARKET POSITION – A LEADER IN SEED2SEED™ VALUE-CHAIN

Growers & Cultivators
A focus on better products through better processes

Product Manufactures
Increasing transparency through the value chain

Retailers
Increased sales by fulfilling consumer needs

Consumers
Expecting better from providers and their products

Regulators
Having meaningful data to create regulations to grow the industry

sales demand

compliance costs

efixii

Only GCAC's Efixii solution streamlines operations & drives consumer demand

GCAC

SOLUTION– 5 TECHNOLOGIES COLLECTIONG DATA FROM GENETICS, CULTIVATION TO CONSUMPTION

efixii
cannabis tech solution

Producers

Blockchain Supported Compliance Software

Regulators

GCAC Announces Commercial Launch of its $5.92m Medical Cannabis Data-Acquisition Platform

September 3, 2020 /

Vancouver, British Columbia, Canada, September 3, 2020 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced the closing of its months-long integration, and its exclusive licensing agreement, with TraceLocker, thereby marking the final step in the [...]

PRESS RELEASE

Track & Trace Portal

Cloud Document Storage

Ethereum App Notarizer

KYC App

GCAC ANNOUNCES EXPANSION OF THE CITIZEN GREEN PLATFORM WITH NEW 3T ("TRACK-TRACE-TREAT") DATA SERVICE FOR MEDICAL CANNABIS GROWERS

August 12, 2020 /

Global Cannabis Applications Corp. is ready to commercially license its new 3T (track-trace-treat) data service following the signing of a sublicensing and integration memorandum of understanding with TraceLocker, an Ethereum blockchain compliance platform for medical cannabis growers and importers. Licensing the Global Cannabis Applications's 3T data acquisition service opens immediate revenue opportunities for the company, [...]

PRESS RELEASE

Tranparent, cryptographically verified public document storage

API

Ethereum API

GCAC Outlines Its Ethereum 2.0 Roadmap for Medical Cannabis

December 1, 2020 /

Vancouver, British Columbia, Canada, December 1, 2020 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading commercial licensor of proprietary blockchain Data and AI technologies to the medical cannabis industry, today outlined its Ethereum 2.0 rollup-centric roadmap, Eth2; continuing its focus on the benefits that Ethereum-truths bring to the Canadian medical [...]

PRESS RELEASE

Identity Management

Producer Employee Wallets
Lab Wallets
Staff Wallets
Regulator Wallets

Ethereum Network

Dapp Smart Contracts

Notarization Contract
Feeless Transactions
Public Ledger
Off-Chain Hash Verification
of Large Documents

$6.5M INVESTMENT OVER 5 YEAR RESULTING IN A $55M+ COMPANY

GCAC

GCAC'S PATENT – OWNING CANNABIS ON THE BLOCKCHAIN

GACP GROW DATA

A1234567890A

CONSUMER TREATMENT FEEDBACK DATA

SEED2SEED™

GCAC's patent is defined "as the process for determining the averaged efficacy of a consumed gram of medical cannabis (or CBD) for the treatment of a specific ailment through the use of an Artificial Intelligence algorithm, which is then stored on an immutable blockchain with the specific growing data of that gram"

GCAC Files Patent Application for Cannabis on the Blockchain

December 19, 2019 /

Vancouver, British Columbia, Canada, December 19, 2019 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading developer of innovative data and AI technologies for the medical cannabis industry, announced that it has filed a provisional method and composition patent application (Serial No. 62/950,158) with the U.S. Patent and Trademark Office [...]

PRESS RELEASE

GCAC

UNDER A SIMPLE QR CODE IS BIG TECHNOLOGY & BIGGER REVENUE

GCAC Announces Commercial Launch of Medical Cannabis Efficacy App

December 15, 2020 /

Efixii platform connects cultivators to consumers while promoting product transparency. The new app allows consumers to rate cannabis efficacy, earn rewards, and purchase reports. Vancouver, British Columbia, Canada, December 15, 2020 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis platform, today announced the launch of Efixii, [...]

PRESS RELEASE

Efixii SaaS Licensing:

CDN$25.6M

Licensing of Cannabis Data:

CDN$23M

Efixii SaaS generates $.20/gram & $.18/gram in blockchain data sales at 65%+ margins – **year over year**

Got a smartphone?
Scan the QR code
and try Efixii yourself!

* forecast includes grams QR coded and grams contracted to be QR coded by Nov 2023.

GCAC

EOY 2022 = 128M grams measured & 3bn data points.

GCAC Announces Health Canada Medical Cannabis Sales License

February 4, 2021 /

Efixii App Gains Health Canada Cannabis-Consultation Feature for $600 Million Market Vancouver, British Columbia, Canada, February 4, 2021 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis chain-of-custody compliance and data platform, today announced it has commenced the licensing process to become a Health Canada Medical Sales License holder [...]

GCAC Announces $0.4m Deal with Europe's Largest CBD Oil Producer

February 22, 2021 /

GCAC Closes Largest Revenue Deal for its Efixii 'Seed to Seed' Platform with Malta Based Medical Cannabis Cultivator

April 13, 2021 /

Phase One Efixii SaaS License for 44M Grams for the 2022 Harvest Vancouver, British Columbia, Canada, April 13, 2021 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis chain-of-custody compliance, efficacy and data platform, today announced a definitive three-year software licensing agreement with Herb Industries Ltd. ("Herb"), a Malta [...]

GCAC Strengthens Its Medical Cannabis Efficacy Platform with Purity-IQ Biotechnology to Address a $4.1 Billion Market Opportunity

October 5, 2020 /

Vancouver, British Columbia, Canada – TheNewswire – October 5, 2020 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE:APP) , FSE: 2FA, (OTC:FUAPF), a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced that it has signed a Memorandum of Understanding ("MOU") with Purity-IQ Incorporated of Canada ("Purity-IQ") (http://purity-iq.com/) to integrate the Purity-IQ Cannabis Authenticity and [...]

GCAC Signs Definitive Reseller Agreement for Efixii into $233 Million Israeli Medical Cannabis Market

January 4, 2021 /

Vancouver, British Columbia, Canada, January 4, 2021 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis data platform, today announced it has signed a Citizen Green Efixii ("Efixii") Reseller & License Agreement ("Agreement") with Transparent-C Ltd. ("Transparent-C"), a provider of regulatory and professional services to Israeli medical cannabis market [...]

Citizen Green Medical Cannabis Data-Acquisition Platform Goes Live with the Signing of a 3-Year SaaS Licensing Deal

October 14, 2020 /

Vancouver, British Columbia, Canada, October 14, 2020 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced a definitive three-year software licensing deal with Bless Cultivation Ltd. ("Bless"), an Israeli based medical cannabis cultivator. This licensing agreement [...]

Region: Canada
Approach: Become a Health Canada non possession seller
Direct/Indirect: Direct Sales
Time frame: Q3 (fully licensed)
Next step: launch cannabis reddit style AI driven web portal for consumers

Region: USA
Approach: Efixii SaaS license to state-by-state cultivators,
And lobbying at state government levels.
Direct/Indirect: Direct Sales
Time frame: Q3
Next step: launch cannabis web portal to select US cannabis consumers in New Jersey and Florida

Region: European Union
Approach: Approach CBD & Cannabis cultivators.
Direct/Indirect: Direct
Time frame: Q1
Next step: EU cultivators currently in pipeline

Region: Israel South America, South Africa
Approach: Franchise Model
Direct/Indirect: Indirect Sales
Time frame: Q2
Next step: Established franchise corporate structure in Lithuania. Israeli & SA growers currently in pipeline

GCAC

SALES + CLEAN BALANCE SHEET = STOCK VALUE GROWTH

As of March

GCAC

ANALYSTS ARE BULLISH ON GLOBAL CANNABIS

April 2021

GCAC

TEAM

BRAD MOORE
CEO & Director

20 years of practical business leadership experience with Fortune 500 companies.
Strong background with internet-based start-up corporations. Proven track record restructuring and developing early-stage businesses.
Holds an MBA from Royal Roads University.

ALEXANDER HELMEL
CFO & Director

14 years of experience in the Canadian capital markets. Over 20 years within the Information Technology sector. Specializes in developing corporate growth strategies, building senior management teams, and developing corporate assets. Intimate knowledge of internal control strategies and corporate governance guidelines. BSc (Mathematics), Certified Information Systems Auditor (CISA) 2006.

HANAN GELBENDORF
CMO

Over 20 years of global marketing experience, in agency and corporate America. Proven record of delivering results for early stage businesses and established F500 companies. Specializes in Leading all the aspects and processes of marketing. Holds an MBA from the Smeal College of Management at PSU.

JEFFREY HAYZLETT
Director

Chairman of C-Suite Network, home of the world's most trusted network of C-Suite leaders, and a notable media personality. CEO of The Hayzlett Group. TV & Radio host, Bloomberg Television & CBS Radio. Global CMO at Eastman Kodak.

NADAV SEAGAL
Medical Cannabis Expert

Active in the field of cannabis for 15 years with extensive experience in research, product development and technologies. Serves as a consultant for research institutes and private companies within Israel and abroad.

ADOLFO GONZALES
Medical Cannabis Advocate

Sought after practitioner, author and advocate of medical cannabis. Created the Cann Help Deck from ten plus years of data aggregated from medical cannabis users.

GCAC

CAPITALIZATION STRUCTURE

GCAC is listed on the CSE Market where other cannabis-related companies continue to lead investment activity.

Head office	Vancouver, BC
Satellite offices	Israel, Lithuania
CSE	APP
FSE	2FA
OTCQB	FUAPF
Shares issued	174,127,509
Warrants & Options	80,437,663
Recent price	$0.215*
Market capitalization	$37,437,414
Avr. daily 45 days	499,875

✓ A true medical cannabis data company using one of a kind technology with a 360 degrees approach to full spectrum data gathering and analysis

✓ Creating a long-term value chain by focusing on patient outcomes and helping the industry offer better & higher margin products

✓ A fully scalable patented model that has no technology limitations and meets all known regulatory requirements

✓ Realistic revenues based on the previous value associated with sale of limited data sets to growers and sellers

Owning a share in GCAC is owning a share in the future of Medical Cannabis data to help grow the acceptance of the use of medical cannabis around the world.

*45 day VWAP

GCAC

WHATS NEXT? EXECUTION, EXECUTION, *REVENUE+++*

GCAC Signs Data Sales Contract for Medical Cannabis Data

January 20, 2021 /

Vancouver, British Columbia, Canada, January 20, 2021 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis chain-of-custody compliance and data platform, today announced it has signed a definitive Data Sales Service Agreement ("Agreement") with Alqami. The partnership will enable GC global buyer network and license the […]

GCAC Closes Largest Revenue Deal for its Efixii 'Seed to Seed' Platform with Malta Based Medical Cannabis Cultivator

April 13, 2021 /

Phase One Efixii SaaS License for 44M Grams for the 2022 Harvest Vancouver, British Columbia, Canada, April 13, 2021 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis chain-of-custody compliance, efficacy and data platform, today announced a definitive three-year software licensing agreement with Herb Industries Ltd. ("Herb"), a Malta […]

GCAC ANNOUNCES EXPANSION PLATFORM WITH NEW 3T ("TRA FOR MEDICAL CANNABIS GROW

August 12, 2020 /

Global Cannabis Applications Corp. is ready to co service following the signing of a sublicensing and integration memorandum of understa TraceLocker, an Ethereum blockchain compliance platform for medical cannabis gro importers. Licensing the Global Cannabis Applications's 3T data acquisition service opens i revenue opportunities for the company, […]

GCAC Announces $0.4m Deal with Europe's Largest CBD Oil Producer

February 22, 2021 /

QR Code Deployment on Initial Run of 400 Liters of CBD Oil from a 24,000 Liter Producer Va British Columbia, Canada, February 22, 2021 – Global Cannabis Applications Corp. ("GCA("Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis chain-of compliance and data platform, today announced it has signed a Memorandum of Under ("Agreement") […]

GCAC Strengthens Its Medical Cannabis Efficacy Platform with Purity-IQ Biotechnology to Address a $4.1 Billion Market Opportunity

October 5, 2020 /

Vancouver, British Columbia, Canada – TheNewswire – October 5, 2020 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE:APP) , FSE: 2FA, (OTC:FUAPF), a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced that it has signed a Memorandum of Understanding ("MOU") with Purity-IQ Incorporated of Canada ("Purity-IQ") (http://purity-iq.com/) to integrate the Purity-IQ Cannabis Authenticity and […]

GCAC Outlines Its Ethereum 2.0 Roadmap for Medical Cannabis

December 1, 2020 /

Vancouver, British Columbia, Canada, December 1, 2020 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading commercial licensor of proprietary blockchain Data and AI technologies to the medical cannabis industry, today outlined its Ethereum 2.0 rollup-centric roadmap, Eth2; continuing its focus on the benefits that Ethereum-truths bring to the Canadian medical […]

GCAC Enters into Definitive Agreement with Purity-IQ Biotechnology

November 10, 2020 /

Vancouver, British Columbia, Canada, November 10, 2020 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading comme of proprietary Data and AI technologies to the medical cannabis industry, today announce signed a Definitive Agreement ("Agreement") with Canadian company Purity-IQ Inc. ("P commercially integrate the Purity-IQ Cannabis […]

Citizen Green Medi Live with the Signir

October 14, 2020 /

Vancouver, British Columbia, Canada, October 14, 2020 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced a definitive three-year software licensing deal with Bless Cultivation Ltd. ("Bless"), an Israeli based medical cannabis cultivator. This licensing agreement […]

GCAC to Give Back to its Shareholders by an 'Enforcement of Security' for a Delinquent $5M Debt Owed to Company

March 11, 2021 /

Vancouver, British Columbia, Canada, March 11, 2021– Global Cannabis Applications ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis -of-custody compliance edings with respect to i shine Technology Corpor:

GCAC Announces Health Canada Medical Cannabis Sales License

February 4, 2021 /

Efixii App Gains Health Canada Cannabis-Consultation Feature for $600 Million Market Vancouver, British Columbia, Canada, February 4, 2021 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis chain-of-custody compliance and data platform, today announced it has commenced the licensing process to become a Health Canada Medical Sales License holder […]

GCAC Signs Definitive Reseller Agreement for Efixii into $233 Million Israeli Medical Cannabis Market

January 4, 2021 /

Vancouver, British Columbia, Canada, January 4, 2021 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis data platform, today announced it has signed a Citizen Green Efixii ("Efixii") Reseller & License Agreement ("Agreement") with Transparent-C Ltd. ("Transparent-C"), a provider of regulatory and :ional services to Israeli medical cannabis market […]

mber 15, 2020 /

i platform connects cultivators to consumers while promoting product transparency.   The new allows consumers to rate cannabis efficacy, earn rewards, and purchase reports.   Vancouver, ish Columbia, Canada, December 15, 2020 – Global Cannabis Applications Corp. ("GCAC" or the npany") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis platform, today ounced the launch of Efixii, […]

Vancouver, British Columbia, Canada, October 29, 2020 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced the expansion of Citizen Green's Software-as-a-Service ("SaaS") commercial licensing to encompass the full medical cannabis product lifecycle. These new SaaS […]

15

GCAC

Better Patient Outcomes
Cannabis Business Growth

Brad Moore
bmoore@cannappscorp.com
+1 514 561 9091

Suite 830, 1100 Melville Street
Vancouver, British Columbia, V6E 4A6

info@cannappscorp.com